PITTSBURGH--(BUSINESS WIRE)--In September, the National Lipid Association’s (NLA) Clinical Lipid Update will feature thought-provoking debates on controversial topics in clinical lipidology and expert presentations on new research in the field of clinical lipidology, covering topics from new pharmacologic interventions to lipid management in special populations.
The regional conference is expected to bring more than 200 clinical lipidologists and health care professionals to the Omni William Penn Hotel in Pittsburgh from September 18 to 20 to learn about the latest research on up-and-coming topics related to lipids and other CV risks.
“The Clinical Lipid Update is a great opportunity for all health care professionals, including physicians, PhD researchers, nurses, nurse practitioners, physician assistants, pharmacists, exercise physiologists, and dietitians, involved in the field of clinical lipidology to learn about the latest developments in their field of practice, and to connect and network with colleagues,” said Linda C. Hemphill, MD, FNLA, president of the Northeast Chapter of the NLA, and one of the program planners for this meeting.
Attendees will have access to three days of scientific sessions, and case presentations. Some of the highlights include:
- Learn about PCSK9 inhibition, and how the latest approved drugs will affect the practice of clinical lipidology, with talks by James M. McKenney, PharmD, CLS, FNLA, and Peter W.F. Wilson, MD, FNLA.
- The impact of weight reduction lipid metabolism and lipid levels, with presentations on how body fat changes affect dyslipidemia by Eric C. Westman, MD, MHS; and the effects of weight management pharmacotherapy on lipid metabolism and lipid levels by Daniel H. Bessesen, MD.
- Debates will be held on controversies in clinical lipidology. Benjamin J. Ansell, MD, FNLA, and Robert S. Rosenson, MD will be debating controversies and new directions of HDL; Patrick E. McBride, MD, MPH, and W. Virgil Brown, MD, FNLA will discuss the necessity of lipoprotein goals and monitoring.
Other topics of discussion will be lipid management in special populations with a focus on the NLA Recommendations Part 2, and the management of barriers to ASCVD risk reduction.
Additionally, there will be two pre-conference workshops offered, including the Masters in Lipidology Course and the Lipid Academy. “These are very intensive approaches to clinical lipidology, providing a wide overview of the field for those who want the highest level of academic excellence and knowledge in terms of patient care,” Hemphill said.
For more information on the NLA Clinical Lipid Update, visit www.lipid.org/fallclu.
About the National Lipid Association
The NLA is a multidisciplinary specialty society focused on prevention of cardiovascular disease and other lipid-related disorders. The NLA’s mission is to enhance the practice of lipid management in clinical medicine, and their goals is to enhance efforts to reduce death and disability related to disorders of lipid metabolism in patients.
